Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early levodopa feasibility trial in infants with oculocutaneous albinism
ISRCTN11828672Phase 3Recruiting
- Sponsor
- University Hospital Southampton NHS Foundation Trust
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of levodopa and carbidopa in Oculocutaneous albinism (OCA), sponsored by University Hospital Southampton NHS Foundation Trust. Started Aug 2026; status: recruiting.
02
Drugs
levodopacarbidopa
03
Conditions
Oculocutaneous albinism (OCA)
Beyond the preview
Go deeper on ISRCTN11828672.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11828672.